Search research articles
Contact Us
Filters
Showing results (71-80 of 186) with videos related to
Page
of 19
Sort By:
Gut
|
March 3, 2009
MHC Class II alleles in ulcerative colitis-associated colorectal cancer
M M Garrity-Park, E V Loftus, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
November 19, 2010
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study
S Schreiber, I C Lawrance, O Ø Thomsen, et al.
Alimentary Pharmacology & Therapeutics
|
December 1, 2010
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine
T Tang, S R Targan, Z-S Li, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
April 29, 1998
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis
A G Kaditis, J Perrault, W J Sandborn, et al.
Gut
|
September 14, 2004
CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial
W J Sandborn, B G Feagan, G Radford-Smith, et al.
Alimentary Pharmacology & Therapeutics
|
November 22, 2017
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
N Vande Casteele, B G Feagan, S Vermeire, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|
December 15, 2007
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial
S B Hanauer, W J Sandborn, C Dallaire, et al.
Gut
|
February 15, 2008
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
M A Kamm, G R Lichtenstein, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
December 9, 2016
Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy
M Fumery, P S Dulai, P Meirick, et al.
Cancer
|
March 5, 1998
Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study
K W Nuako, D A Ahlquist, W J Sandborn, et al.
Page
of 19
Search research articles
Search
Showing results (71-80 of 186) with videos related to
Sort By:
Page
of 19
Gut
|
March 3, 2009
MHC Class II alleles in ulcerative colitis-associated colorectal cancer
M M Garrity-Park, E V Loftus, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
November 19, 2010
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study
S Schreiber, I C Lawrance, O Ø Thomsen, et al.
Alimentary Pharmacology & Therapeutics
|
December 1, 2010
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine
T Tang, S R Targan, Z-S Li, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
April 29, 1998
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis
A G Kaditis, J Perrault, W J Sandborn, et al.
Gut
|
September 14, 2004
CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial
W J Sandborn, B G Feagan, G Radford-Smith, et al.
Alimentary Pharmacology & Therapeutics
|
November 22, 2017
Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
N Vande Casteele, B G Feagan, S Vermeire, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|
December 15, 2007
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial
S B Hanauer, W J Sandborn, C Dallaire, et al.
Gut
|
February 15, 2008
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
M A Kamm, G R Lichtenstein, W J Sandborn, et al.
Alimentary Pharmacology & Therapeutics
|
December 9, 2016
Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy
M Fumery, P S Dulai, P Meirick, et al.
Cancer
|
March 5, 1998
Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study
K W Nuako, D A Ahlquist, W J Sandborn, et al.
Page
of 19